Sejin Oh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sejin Oh has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Jihye Park
Department of Dermatology, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul 06351, Republic of Korea
1 shared publication - Jong Hee Lee
Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
1 shared publication - Ju Heon Park
Department of Dermatology, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul 06351, Republic of Korea
1 shared publication - YoungHwan Choi
Department of Dermatology, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul 06351, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 17 June 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (12) , 4312
Predicting Favorable Conditions for the Determination of Initial Use of Janus Kinase Inhibitors in Patients with Moderate to Severe Atopic Dermatitis
Background: Numerous novel medications are being developed to treat moderate to severe atopic dermatitis (AD), notably biologics and Janus kinase inhibitors (JAKis). However, the exact guideline for the first determination of which medication has not been established yet. This study was conducted to identify patients who would show favorable clinical results from using JAKis. Methods: Based on the degree of improvement in EASI at 16 weeks, 43 patients were divided into three groups: Group 1 (EASI-90), Group 2 (EASI-75), and Group 3 (EASI-50). Results: Compared to Group 1 and Group 2, Group 3 exhibited a significantly higher rate of multiple positive results in MAST (p-value = 0.005, p-value = 0.004), a greater proportion of individuals with higher IgE levels exceeding 1000 (p-value = 0.003, p-value = 0.027), and the presence of allergic comorbidities (p-value = 0.049, p-value = 0.026). However, baseline laboratory test results, such as eosinophil counts, LDH, and so on, showed no significant differences among the three groups. Conclusions: JAKis might provide prompt clinical improvement, especially in patients with relatively low serum Ig E levels who do not have multiple allergen positivities and allergic comorbidities.
- 17 June 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (12) , 4312
Open AccessPredicting Favorable Conditions for the Determination of Initial Use of Janus Kinase Inhibitors in Patients with Moderate to Severe Atopic Dermatitis
Background: Numerous novel medications are being developed to treat moderate to severe atopic dermatitis (AD), notably biologics and Janus kinase inhibitors (JAKis). However, the exact guideline for the first determination of which medication has not been established yet. This study was conducted to identify patients who would show favorable clinical results from using JAKis. Methods: Based on the degree of improvement in EASI at 16 weeks, 43 patients were divided into three groups: Group 1 (EASI-90), Group 2 (EASI-75), and Group 3 (EASI-50). Results: Compared to Group 1 and Group 2, Group 3 exhibited a significantly higher rate of multiple positive results in MAST (p-value = 0.005, p-value = 0.004), a greater proportion of individuals with higher IgE levels exceeding 1000 (p-value = 0.003, p-value = 0.027), and the presence of allergic comorbidities (p-value = 0.049, p-value = 0.026). However, baseline laboratory test results, such as eosinophil counts, LDH, and so on, showed no significant differences among the three groups. Conclusions: JAKis might provide prompt clinical improvement, especially in patients with relatively low serum Ig E levels who do not have multiple allergen positivities and allergic comorbidities.